

September 2025

# ProteanFect™ TuffCell Transfection Kit



0.02 mL (cat. no. TT300007S)

0.1 mL (cat. no. TT300007M)

1.0 mL (cat. no. TT300007L)

A non-viral, non-electroporation, non-liposomal transfection kit using engineered mammalian proteins, tailored for high-efficiency delivery into a wide range of primary cells and difficult to transfect cell lines such as immune cells, stem cells, and neuronal cells.

**RUO**

For Research Use Only



[www.origene.com](http://www.origene.com)

**REF**

TT300007S, TT300007M, TT300007L



OriGene, 9620 Medical Center Drive, Rockville,  
MD 20850, USA. Phone: + 1-301-340-3188

## Product Overview

ProteanFect™ TuffCell Transfection Kit offers a non-viral, non-electroporation, and non-liposomal transfection system utilizing engineered mammalian proteins. This innovative design achieves high transfection efficiency while maintaining a superior safety profile. Specifically developed for hard-to-transfect cell lines and challenging primary cells, the kit ensures robust performance across a broad range of cell types (refer to Table 4). Additionally, it is easily scalable for large-scale experiments and ideal for high-throughput applications.

## Component Description

The kit is shipped on dry ice. Once received, store the components as indicated below. The kit includes control payloads EGFP-encoding mRNA (~1000nt) and plasmid DNA (~7kb) to verify transfection efficiency.

**Table 1. Storage Conditions for the Components**

| Component             | Storage |
|-----------------------|---------|
| Reagent A             | 2-8°C   |
| Reagent B             | -20°C   |
| Reagent C             | 2-8°C   |
| EGFP mRNA (1 ug/uL)   | -20°C   |
| EGFP pDNA (0.5 ug/uL) | -80°C   |

**Note:** Avoid freeze-thawing Reagent B more than 10 times, and prepare aliquots of at least 20 µL. Positive controls, given their small volume, do not require this limit and can follow standard handling guidelines for mRNA and plasmids.

---

## In Preparation:

**Cell Condition:** Ensure cells are in optimal physiological condition on the day of transfection, with >90% viability. For certain primary cells, such as human primary T cells, proper activation before transfection is crucial for optimal results.

**Reagent:** Allow Reagents A, B, and C to reach room temperature before use. Briefly mix thoroughly each reagent by gently inverting or brief vortexing before use.

**Nucleic acids:** High-purity nucleic acids are essential for efficient transfection. All nucleic acids should be dissolved in nuclease-free water free of salts, and the final concentration adjusted to 0.5–2 µg/µL before use. Plasmid DNA should be prepared using an endotoxin-free purification kit and exhibit an OD<sub>260/280</sub> ratio between 1.7 and 1.9. Endotoxin may markedly decrease transfection efficiency.

**Transfection Medium:** Fetal bovine serum (FBS) or other serum markedly impairs transfection, and additional proteins or excess salt ions may also interfere. Pre-warm the medium to 37°C or room temperature before use.

Recommended media:

- Opti-MEM (preferred)
- Serum-free RPMI 1640 or DMEM (alternatives)

# Transfection Procedure

*Important Tip: Thorough mixing during complex preparation is crucial for proper coacervate formation — this is the key difference from liposome-based transfection. Inadequate mixing is a common reason for failed transfections.*

**Table 2. Transfection Protocol for mRNA per well of a 96-well plate**

| Steps   | Instructions for Cell Lines  | Instructions for Primary Cells <sup>a</sup>   |
|---|--|---|
| <b>1. Transfection Complex Preparation <sup>b</sup></b> |  |   |
| 1.1. Mix Reagent A with the payload                     | Mix the required amount of nucleic acids (see Table 3; 0.5 µg DNA or mRNA per well of a 96-well plate) with 40 µL Reagent A. Briefly invert the tube before use to ensure reagent uniformity.  |   |
| 1.2 Add Reagent B                                       | Add Reagent B as specified in Table 3 (i.e. 1 µL Reagent B for DNA or 1.4 µL Reagent B for mRNA). Mix thoroughly by pipetting up and down 20–30 times or vortexing for 10 s.<br>Place the transfection complex on ice before adding to cells.<br><b>Note:</b> Thorough mixing is essential for optimal performance.  | Add 0.7 µL Reagent B to the mixture. Mix thoroughly by pipetting 20–30 times or vortexing for 10 s. Place the transfection complex on ice before adding to cells.<br><b>Note:</b> Thorough mixing is essential for optimal performance. |
| 1.3 Add Reagent C                                       | <b>Optional:</b> Add 8 µL of Reagent C and mix gently by pipetting 2–3 times or vortexing for 2–3 s. Reagent C is not required for most cell lines but may improve efficiency in hard-to-transfect types.  | Add 8 µL of Reagent C to the mixture. Mix gently by pipetting up and down 2–3 times or vortexing for 2–3 seconds.   |
| <b>2. Cell Preparation</b>                              |  |   |
| 2.1 Suspension cells                                    | Harvest the cells by centrifugation at 300 g for 5 minutes. Discard the supernatant and wash cells once with Opti-MEM. Resuspend cells with Opti-MEM and adjust concentration to 5×10 <sup>6</sup> - 1×10 <sup>7</sup> cells/mL.<br><b>Note:</b> Ensure the transfection medium contains no FBS or serum.  |   |
| 2.2 Adherent cells                                      | Ensure cells are at 50–80% confluency. Remove culture medium, wash once with Opti-MEM, and add 20 µL Opti-MEM. Adherent cells may also be trypsinized and transfected in suspension (follow instructions for suspension cells).<br><b>Note:</b> Suspension transfection may yield higher efficiency for some adherent lines. Consider testing both formats. Ensure the transfection medium contains no FBS or serum. |   |
| <b>3. Transfection</b>                                  |  |   |
| 3.1 Mix transfection complex with cells                 | For suspension transfection, mix the transfection complex with 20 µL of cell suspension in an Eppendorf tube and gently pipet up and down 2–3 times. For adherent transfection, apply directly to the seeded cells.  |   |
| 3.2 Incubation  | With Reagent C: 15–30 min in incubator.<br>Without Reagent C: Incubate the tube containing cells and the transfection complex for 30–60 min in a cell culture incubator.   | Incubate the cells with the transfection complex for 15–30 minutes in a cell culture incubator.   |
| 3.3 Termination   | For suspension transfection, add ≥200 µL of complete culture medium (at least 10×cell suspension), then transfer the cells from the tube to the culture plate (a well of 96-well plate). For adherent transfection, replenish with ≥200 µL of complete culture medium.   |   |
| 3.4 Post-transfection culture                           | Incubate transfected cells in culture medium and assess transfection efficiency after 5 to 48 hours, or at an appropriate time point for your experiment.  |   |

**a.** Proper activation is crucial for primary cells, such as human primary T cells, which should be stimulated with anti-CD3/CD28 beads or antibodies for 2–10 days to achieve optimal transfection efficiency. **b.** The transfection complex may become slightly viscous during preparation. It can be directly added to cells once prepared without incubation. **For optimal results, use the complex within 30 minutes.**

**Table 3. Transfection Guidelines for Different Culture Formats**

| Components   | Culture Vessels <sup>a</sup> | Cell Lines                                       |             |              | Primary Cells |              |
|--|------------------------------|--|-------------|--------------|---------------|--------------|
| <b>Reagent A</b>                                       | 96-well                      | 40 uL  |             |              |               |              |
|  | 48-well                      | 80 uL  |             |              |               |              |
|  | 24-well                      | 200 uL   |             |              |               |              |
|  | 12-well                      | 600 uL   |             |              |               |              |
|  | 6-well                       | 800 uL   |             |              |               |              |
| <b>Nucleic Acids <sup>b</sup></b>                      |                              | <b>DNA</b>                                       | <b>mRNA</b> | <b>siRNA</b> | <b>mRNA</b>   | <b>siRNA</b> |
|  | 96-well                      | 0.2-0.5 ug                                       | 0.2-1.0 ug  | 20-40 pmol   | 0.2-1.0 ug    | 20-40 pmol   |
|  | 48-well                      | 0.4-1.0 ug                                       | 0.4-2.0 ug  | 40-80 pmol   | 0.4-2.0 ug    | 40-80 pmol   |
|  | 24-well                      | 1.0-2.5 ug                                       | 1.0-5.0 ug  | 100-200 pmol | 1.0-5.0 ug    | 100-200 pmol |
|  | 12-well                      | 3.0-7.5 ug                                       | 3.0-15.0 ug | 300-600 pmol | 3.0-15.0 ug   | 300-600 pmol |
|  | 6-well                       | 4.0-10.0 ug                                      | 4.0-20.0 ug | 400-800 pmol | 4.0-20.0 ug   | 400-800 pmol |
| <b>Reagent B</b>                                       | 96-well                      | 1 µL   | 1.4 µL      | 1.4 µL       | 0.7 µL        |              |
|  | 48-well                      | 2 µL   | 2.8 µL      | 2.8 µL       | 1.4 µL        |              |
|  | 24-well                      | 5 µL   | 7 µL        | 7 µL         | 3.5 µL        |              |
|  | 12-well                      | 15 µL  | 21 µL       | 21 µL        | 10.5 µL       |              |
|  | 6-well                       | 20 µL  | 28 µL       | 28 µL        | 14 µL         |              |
| <b>Reagent C</b>                                       | 96-well                      | NA   |             |              | 8 µL          |              |
|  | 48-well                      |  |             |              | 16 µL         |              |
|  | 24-well                      |  |             |              | 40 µL         |              |
|  | 12-well                      |  |             |              | 120 µL        |              |
|  | 6-well                       |  |             |              | 160 µL        |              |
| <b>Recommended Cell Number (Opti-MEM) <sup>c</sup></b> | 96-well                      | 1×10 <sup>5</sup> ~ 2×10 <sup>5</sup> (20 µL)    |             |              |               |              |
|  | 48-well                      | 2×10 <sup>5</sup> ~ 4×10 <sup>5</sup> (40 µL)    |             |              |               |              |
|  | 24-well                      | 5×10 <sup>5</sup> ~ 1×10 <sup>6</sup> (100 µL)   |             |              |               |              |
|  | 12-well                      | 1.5×10 <sup>6</sup> ~ 3×10 <sup>6</sup> (300 µL) |             |              |               |              |
|  | 6-well                       | 2×10 <sup>6</sup> ~ 4×10 <sup>6</sup> (400 µL)   |             |              |               |              |

**a.** For large-scale transfections, such as in 48-well plates or larger formats, it is recommended to use centrifuge tubes for the transfection process. **b.** When co-transfecting multiple nucleic acids, please ensure the total amount of nucleic acids added matches the recommended quantities for each plate format, as outlined in Table 3. **c.** The recommended cell number is primarily for suspension cells. **For adherent cells, please adjust the cell number based on confluency.**

**Table 4. Primary Cells and Cell Lines Successfully Transfected Using ProteanFect™ TuffCell Transfection Kit**


|                   | <b>Cell Type</b>                                    | <b>Tested Nucleic Acids</b> | <b>Transfection Efficiency</b> |
|-------------------|---|-----------------------------|--------------------------------|
| <b>Cell Lines</b> | Human T Cells                                       | mRNA, siRNA                 | 50-100%                        |
|                   | Human B Cells                                       | mRNA, siRNA                 | 50-75%                         |
|                   | Human Natural Killer Cells                          | mRNA, siRNA                 | 25-75%                         |
|                   | iPSCs (Induced Pluripotent Stem Cells)              | pDNA, mRNA, siRNA           | 50-100%                        |
|                   | HSCs (Human CD34+ Hematopoietic Stem Cells)         | mRNA, siRNA                 | 50-100%                        |
|                   | UC-MSCs (Umbilical Cord Mesenchymal Stem Cells)     | mRNA, siRNA                 | 50-100%                        |
|                   | Human Skin Fibroblasts                              | pDNA, mRNA, siRNA           | 50-100%                        |
|                   | KSL (Mouse Hematopoietic Stem Cells)                | mRNA, siRNA                 | 50-100%                        |
|                   | Mouse Neurons                                       | pDNA, mRNA, siRNA           | 10-50%                         |
|                   | Mouse Oligodendrocytes                              | pDNA, mRNA, siRNA           | 50-100%                        |
|                   | Porcine Macrophages                                 | mRNA, siRNA                 | 50-75%                         |
|                   | Bovine Fibroblasts                                  | mRNA, siRNA                 | 50-100%                        |
|                   | M. rosenbergii Hemocytes                            | mRNA, siRNA                 | 25-75%                         |
|                   | Chicken Primordial Germ Cells                       | mRNA, siRNA                 | 25-100%                        |
|                   | L. crocea Mesenchymal Stem Cells                    | mRNA, siRNA                 | 25-50%                         |
|                   | Jurkat (Human T Cells)                              | pDNA, mRNA, siRNA           | 50-100%                        |
|                   | MOLT-16 (Human T-ALL Cells)                         | mRNA, siRNA                 | 10-30%                         |
|                   | Raji (Human B Cells)                                | mRNA, siRNA                 | 50-100%                        |
|                   | MEC-1 (Human B Cells)                               | mRNA, siRNA                 | 50-100%                        |
|                   | TMD8 (Human Diffuse Large B-Cell Lymphoma Cells)    | mRNA, siRNA                 | 50-100%                        |
|                   | NK-92 (Human Natural Killer Cells)                  | mRNA, siRNA                 | 25-75%                         |
|                   | K562 (Human Chronic Myeloid Leukemia)               | pDNA, mRNA, siRNA           | 30-100%                        |
|                   | THP-1 (Human Monocytic Cells)                       | mRNA, siRNA                 | 50-100%                        |
|                   | Kasumi-1 (Human Acute Myeloid Leukemia)             | mRNA, siRNA                 | 50-100%                        |
|                   | MDS-L (Human Leukemia Cells)                        | mRNA, siRNA                 | 50-100%                        |
|                   | U937 (Human Myeloid Leukemia)                       | mRNA, siRNA                 | 50-75%                         |
|                   | HL-60 (Human Promyelocytic Leukemia)                | mRNA, siRNA                 | 50-100%                        |
|                   | HFF (Human Fibroblasts)                             | mRNA, siRNA                 | 50-100%                        |
|                   | LX-2 (Human Hepatic Stellate Cells)                 | pDNA, mRNA, siRNA           | 50-100%                        |
|                   | HepG2 (Human Liver Carcinoma)                       | pDNA, mRNA, siRNA           | 25-75%                         |
|                   | KYSE-510 (Human Esophageal Squamous Cell Carcinoma) | mRNA, siRNA                 | 50-100%                        |

**Table 4. Primary Cells and Cell Lines Successfully Transfected Using ProteanFect™ TuffCell Transfection Kit**

|   | <b>Cell Type</b>                              | <b>Tested Nucleic Acids</b> | <b>Transfection Efficiency</b> |
|---|---|-----------------------------|--------------------------------|
| <b>Cell Lines</b>                           | Mum2B (Human Melanoma)                        | mRNA, siRNA                 | 50-100%                        |
|   | H1-hESC (Human Embryonic Stem Cells)          | pDNA, mRNA, siRNA           | 50-100%                        |
|   | U2OS (Human Osteosarcoma)                     | pDNA, mRNA, siRNA           | 50-100%                        |
|   | HT-29 (Human Colorectal Adenocarcinoma Cells) | pDNA, mRNA, siRNA           | 50-100%                        |
|   | 5637 (Human Bladder Carcinoma Cells)          | pDNA, mRNA, siRNA           | 50-100%                        |
|   | HGC-27 (Human Gastric Carcinoma Cells)        | mRNA, siRNA                 | 50-100%                        |
|   | SH-SY5Y (Human Neuroblastoma Cells)           | pDNA, mRNA, siRNA           | 50-100%                        |
|   | U251MG Cells (Human Glioblastoma Cells)       | mRNA, siRNA                 | 50-100%                        |
|   | HEK293 (Human Embryonic Kidney Cells)         | pDNA, mRNA, siRNA           | 50-100%                        |
|   | Neuro 2A (Mouse Neuroblastoma Cells)          | pDNA, mRNA, siRNA           | 50-100%                        |
|   | MC38 (Mouse Colon Adenocarcinoma Cells)       | mRNA, siRNA                 | 25-75%                         |
|   | RAW264.7 (Mouse Macrophages)                  | mRNA, siRNA                 | 25-50%                         |
|   | LLC (Mouse Lewis Lung Carcinoma)              | pDNA, mRNA, siRNA           | 50-100%                        |
|   | CH12 (Mouse Lymphoma Cells)                   | mRNA, siRNA                 | 50-100%                        |
|   | BV-2 (Mouse Microglial Cells)                 | mRNA, siRNA                 | 25-50%                         |
|   | C2C12 (Mouse Myoblasts)                       | pDNA, mRNA, siRNA           | 50-100%                        |
|   | B16 (Mouse Melanoma Cells)                    | mRNA, siRNA                 | 25-75%                         |
|   | MH-S (Mouse Macrophages)                      | mRNA, siRNA                 | 25-50%                         |
|   | MODE-K (Mouse Intestinal Epithelial Cells)    | mRNA, siRNA                 | 50-100%                        |
|   | MEF (Mouse Embryonic Fibroblasts)             | pDNA, mRNA, siRNA           | 25-100%                        |
|   | 3T3 (Mouse Embryonic Fibroblasts)             | mRNA, siRNA                 | 25-50%                         |
|   | OLN93 (Rat Oligodendrocyte Cells)             | mRNA, siRNA                 | 50-100%                        |
|   | MDBK (Bovine Kidney Epithelial Cells)         | mRNA, siRNA                 | 50-100%                        |
|   | MAC-T (Bovine Mammary Epithelial Cells)       | mRNA, siRNA                 | 50-100%                        |
| COS-7 (Monkey Kidney Fibroblast-like Cells) | pDNA, mRNA, siRNA                             | 50-100%                     |                                |

# Application Data:



## Case 1: Successful Transfection of Jurkat T Cells




- **Cell Type:** Jurkat T Cells
- **Transfected Nucleic Acid Type:** EGFP pDNA or EGFP mRNA
- **Detection Time:** 48 hours post-pDNA transfection; 24 hours post-mRNA transfection

## Case 2: Successful Transfection of primary human T Cells

24 hours post-transfection




Sustained gene expression



- **Cell Type:** Primary human T cells continuously activated for 6 days using Dynabeads™ Human T-Expander CD3/CD28 (Thermo Fisher, 11141D).
- **Transfected Nucleic Acid Type:** EGFP mRNA.
- **Detection Time:** Continuous monitoring from 5 hours to 12 days post-transfection.

## Application Data:



---

# Frequently Asked Questions (FAQs) and Troubleshooting Guide

## 1. Low Transfection Efficiency

### 1.1 Optimize Transfection Parameters

Optimize transfection parameters for each cell type. Extended incubation time: Adjust the incubation time of the transfection complex with cells. The maximum incubation time is 2 hours for cell lines, and 30 minutes for primary cells. Increase ProteanFect transfection complex: Consider increasing the amount of transfection complex to improve transfection efficiency.

### 1.2 Severe Cytotoxicity Caused by Plasmid DNA

The transfection of pDNA into primary cells, such as primary T cells, can induce cytotoxicity and inflammatory responses. Due to the risk of significant toxicity, pDNA transfection is generally not recommended for primary T cells.

### 1.3 Use Positive Control

We recommend using a 96-well plate format to optimize transfection conditions for a specific cell type, with EGFP mRNA as the positive control.

## 2. Low Cell Viability

Transfected cells may exhibit transient changes in behavior, but typically, viability will be restored by the second day post-transfection.

---

**OriGene Headquarters**

9620 Medical Center Dr Rockville, MD 20850  
+1-301-340-3188  
custsupport@origene.com  
techsupport@origene.com  
sales@origene.com

**OriGene EU**

SchillerstraBe 5  
32052 Herford, Germany  
+49-5221-346060-0  
info-de@origene.com